Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients

Trial Title: Multicentric and Retrospective Analysis of Adolescent Young Adult (AYA) Hodgkins' Lymphoma Patients

NCT ID: NCT05663983

Condition: Hodgkin Lymphoma
Adolescent Behavior
Chemotherapy Effect

Conditions: Official terms:
Lymphoma
Hodgkin Disease

Study type: Observational [Patient Registry]

Overall status: Not yet recruiting

Study design:

Time perspective: Other

Intervention:

Intervention type: Behavioral
Intervention name: Description of therapeutical results
Description: Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
Arm group label: AIEOP
Arm group label: FIL

Summary: The principal aim of this study is to collect retrospectively all Adolescent Young Adult patients affected by Hodgkin's Lymphoma and treated in pediatric or adult haemato-oncology Centers. The data set collection aims to define the therapy performed and the results obtained in terms of overall survival and acute or late complications.

Detailed description: Hodgkin lymphoma (HL) represents approximately 0.5% of cancer diagnosis each year in developed countries (1, 2). This translates to an annual incidence of 8500 individuals per year in the United States and an incidence rate of 2.49 per 100.000 lymphoid malignancies in Europe (2, 3). A classical bimodal distribution is reported with a first peak occurring in patients between the ages of 15 and 30 years and a second peak in those older than 55 years (4). HL is one of the most common malignancies to occur in the adolescent and young adult (AYA) population. This population is defined by the National Cancer Institute as people diagnosed with cancer between the ages of 15 and 39 years. The choice of therapy for AYA patients is typically determined by the treatment setting and referral patterns. Patients who are younger than 18 years are usually referred to pediatric Centers, where many patients are treated in the context of clinical trials. For patients treated by adult haematologists many are treated in the community setting. Considerable variability exists between the treatment of adult and pediatric patients, including the choice of chemotherapeutic agents and the role of radiation. In both the pediatric and adult settings there has been increasing focus on balancing the risk of relapse with the risk of secondary side effects. De-intensification for low-risk patients using PET-adapted strategies is a modern approach that has been applied to all patients with HL independent of age. Variability among age groups still results in uncertainty regarding the optimal treatment approach in the AYA population. This is a retrospective observational study involving Italian Centers that treat adolescents and young adults Hodgkin lymphoma patients. This type of patients can be treated either in a Pediatric Institution or in Adult Institution with different supportive and therapeutical approaches. The primary objectives will be overall survival according to different treatment. Secondary end points will be acute or late complications comparing different treatments choice in an homogeneous group of patients, progression free survival according to different treatment.

Criteria for eligibility:

Study pop:
This is a retrospective observational study involving Italian Centers that treat adolescents and young adults Hodgkin lymphoma patients. This type of patients can be treated either in a Pediatric Institution or in Adult Institution with different supportive and therapeutical approaches.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - All consecutive patients with diagnosis of Hodgkin Lymphoma with an age at diagnosis ranging between 15 and 24 years enrolled in prospective studies either in AIEOP group and in FIL group or patients treated consecutively in single centers affiliated to AIEOP or FIL and registered in single institutional data base. - All Hodgkin subtype Exclusion Criteria: - None

Gender: All

Minimum age: 15 Years

Maximum age: 24 Years

Healthy volunteers: No

Start date: January 2023

Completion date: December 2024

Lead sponsor:
Agency: Campus Bio-Medico University
Agency class: Other

Collaborator:
Agency: Associazione Italiana di Ematologia e Oncologia Pediatrica
Agency class: Other

Collaborator:
Agency: Fondazione Italiana Linfomi
Agency class: Other

Source: Campus Bio-Medico University

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05663983